Kura Oncology, Inc. (KURA) stock
Close on Nov 11, 2026Market cap $687.67MP/E –Yield –
Kura Oncology, Inc. reported revenue of $79.31M for the twelve months to Sep 30, 2026. Free cash flow was -$89.12M, down 207.2% from a year earlier. At the latest close the market valued the company at $687.67M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $687.67M
- P/E ratio
- –
- Price to sales
- 8.67
- Price to book
- 38.29
- Dividend yield
- –
- Free cash flow yield
- -12.96%
Fundamentals
- Revenue
- $79.31M
- Net income
- -$292.87M
- EPS, diluted
- -$3.30
- Free cash flow
- -$89.12M
- Book value per share
- $0.20
- Diluted shares
- 90M
Trading
- Next earnings
- Mar 4, 2027 (estimated, before the open)
- Previous close
- $7.57
- Open
- $7.79
- Day's range
- $7.60 – $8.26
- Volume
- 3,653,253
- Average volume (20 days)
- 2,287,083
- Index membership
- Russell 2000, Russell 3000
- Beta (5 years)
- 1.29
- 52-week range
- $6.75 – $13.90
- RSI (14 days)
- 34.7
- Volatility (1 year)
- 62.7%
- Relative volume
- 1.94×
- WACC
- 11.3%
On 2 of our idea lists: More cash than they're worth, Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2015, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | KURA | S&P 500 | Difference | KURA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -27.1% | -2.4% | −24.7 pts | ||
| 3 months | -22.2% | -1.2% | −21.0 pts | ||
| Year to date | -25.6% | +12.3% | −37.9 pts | ||
| 1 year | -27.7% | +12.4% | −40.1 pts | ||
| 3 years | -9.3% | +78.8% | −88.1 pts | -3.2% | +21.4% |
| 5 years | -55.9% | +75.2% | −131.0 pts | -15.1% | +11.9% |
| 10 years | +48.7% | +311.1% | −262.4 pts | +4.0% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Kura Oncology filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Kura Oncology
Pharmaceutical Preparations
Kura Oncology, Inc. is a commercial-stage biopharmaceutical company that discovers, develops, and commercializes precision medicines for the treatment of cancer. The company focuses on small-molecule drug candidates that target cancer signaling pathways to address unmet needs in oncology and hematology. Its approved product is KOMZIFTI (ziftomenib), an oral menin inhibitor administered once daily. The company also advances drug candidates across clinical trials, including evaluation in combination therapies for acute myeloid leukemia. Its therapies primarily serve adult cancer patients, particularly those diagnosed with relapsed or refractory acute myeloid leukemia harboring susceptible nucleophosmin 1 mutations.
Company profile, executives and historyKura Oncology stock: common questions
What is Kura Oncology's stock price?
KURA closed at $7.73 on Nov 11, 2026, up 2.11% on the day. Over the past 52 weeks it traded between $6.75 and $13.90.
What is Kura Oncology's market cap?
Kura Oncology was worth $687.67M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is KURA's P/E ratio?
Kura Oncology lost money over the twelve months to Sep 30, 2026 (diluted EPS -$3.30), so it has no meaningful P/E ratio.
How much revenue does Kura Oncology make?
Kura Oncology reported revenue of $79.31M for the twelve months to Sep 30, 2026.
Does Kura Oncology pay a dividend?
No. Kura Oncology has not paid a cash dividend over the last twelve months.
When does Kura Oncology report earnings next?
Kura Oncology is expected to report Q4 FY2026 results on Mar 4, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has KURA stock performed over the past year?
Including dividends, KURA returned -27.7% over the past year, against +12.4% for the S&P 500.
How many KURA shares are sold short?
13M shares were sold short at the latest FINRA report, 14.57% of the float, or 7.9 days of average trading volume.
Who are Kura Oncology's competitors?
Companies most similar to Kura Oncology by business, industry and size include VSTM, TNGX, NUVB, PRLD, RCUS.
See a number that looks wrong?